STYLAGE® XL BI-FLEX® with Lidocaine

Description

Name: STYLAGE® XL BI-FLEX® with Lidocaine
Manufacturer: Vivacy
Active Substance(s): CROSS-LINKED HYALURONIC ACID (HA), MANNITOL, LIDOCAINE
Strength: 26mg/g HA, 3mg/ml Lidocaine
Package Content: 2 x 1ml Pre-Filled Syringes, 2 x 23G Needles, 2 x 27G Needles

STYLAGE® XL BI-FLEX® with Lidocaine carries the highest hyaluronic acid concentration in the STYLAGE® range, formulated with 26mg/g cross-linked HA and 3mg/mL lidocaine by Laboratories VIVACY, France. Designed for significant volume restoration and structural facial contouring, it combines IPN-Like Technology™ with the BI-FLEX® syringe system. It was rebranded from Bi-SOFT® for improved ergonomics, precision, and safety. Intended for severe volume loss and deep structural contouring when lighter STYLAGE® formulations are insufficient, it is supplied as 2 × 1mL prefilled syringes with 2 × 27G ½” needles. Practitioners seeking to buy STYLAGE® XL BI-FLEX® with Lidocaine online may contact Maylips support team for guidance.

• Strength: 26mg/g HA | 3mg/mL Lidocaine
• Active Ingredient: Hyaluronic acid (cross-linked) 26mg/g; Lidocaine 3mg/mL
• Dosage Form: Injectable gel — 2 × 1mL prefilled syringes (BI-FLEX® syringe system) + 2 × 27G ½” needles
• FDA Approval Date: STYLAGE® is NOT FDA-approved for U.S. use. The product carries CE marking for European Union markets only (CE certification for medical devices under the EU MDR).
• Molecular Type: Cross-linked hyaluronic acid (IPN-Like Technology™) with lidocaine
• Intended Use: Severe volume loss, deep facial volumization, and structural contouring — for licensed aesthetic professionals; use when lighter STYLAGE® formulations are insufficient
• Brand: STYLAGE®
• Country of Origin: France
• Manufacturer: Laboratories VIVACY (Paris, France)

STYLAGE® XL is engineered specifically for patients with severe facial volume loss and advanced structural deficiencies.

• Maximum Lifting Capacity: Formulated at 26mg/g of cross-linked hyaluronic acid, it delivers the highest HA concentration in the STYLAGE® dermal filler portfolio.
• Superior Projection: This high density makes it far better suited for deep volumization and contouring than lighter formulations like STYLAGE® L (24mg/g) or STYLAGE® M (20mg/g).

IPN-Like Technology™ & Resilience

The formulation leverages proprietary IPN-Like Technology™, which develops interpenetrating hyaluronic acid polymer networks. This specific molecular architecture:

• Enhances gel cohesivity and durability.
• Maximizes resistance to mechanical stress.
• Maintains structural integrity and support in highly dynamic areas of the face subject to constant movement, ensuring long-lasting volumizing effects.

The BI-FLEX® Delivery System Rebrand

The BI-FLEX® designation represents Laboratories VIVACY’s ergonomic transition from the legacy Bi-SOFT® syringe platform.

• Precision Control: Optimized syringe ergonomics improve injection precision, allowing practitioners to maintain controlled delivery when navigating deep subcutaneous and supraperiosteal planes.

Clinical Rationale for Integrated Lidocaine

Deep-plane injections at the subcutaneous or supraperiosteal level target highly sensitive tissue structures and are inherently more painful than superficial dermal corrections.

• Targeted Pain Management: The co-formulated 3mg/mL lidocaine acts as an integrated amide-type local anesthetic, attenuating nociceptive pain signals directly at the injection site.
• Procedural Efficiency: By eliminating the need for separate nerve blocks, topical compounding creams, or additional needle passes, it significantly enhances patient comfort and streamlines multi-point XL volumization sessions.

For injectors evaluating STYLAGE® for structural work, the combination of maximum HA concentration, IPN-Like Technology™, and the upgraded BI-FLEX® delivery system positions it as a premier option in advanced aesthetic medicine.

STYLAGE® products are CE-marked for European markets under the EU MDR. Practitioners must independently verify local regulatory compliance and licensing requirements before sourcing or procuring this product for clinical use in the United States or other non-CE jurisdictions.

STYLAGE® XL is selected when greater lifting capacity and volumizing power are required than STYLAGE® L or M can deliver. Typical indications include:

• Severe facial volume loss
• Midface and cheek augmentation
• Temple restoration
• Chin projection
• Jawline definition
• Deep structural contouring
• Advanced correction of nasolabial folds and marionette lines with a major volume component

STYLAGE® XL is not indicated for moderate wrinkle correction or superficial lines. For these treatment areas, practitioners should use appropriate lighter formulations. Patient selection requires careful evaluation of the extent of volume loss, skin condition, skin type, facial anatomy, and treatment goals. Because the product is intended for deep-plane injections, appropriate anatomical knowledge and injection expertise are required.

Practitioners comparing injectable dermal fillers when buying online should evaluate intended depth and volumizing capacity to select the most appropriate formulation.

STYLAGE® XL BI-FLEX® with Lidocaine restores volume by introducing 26mg/g cross-linked HA into areas affected by age-related fat loss, tissue descent, and structural depletion. Once injected, the gel binds water molecules and provides immediate volumizing support while helping maintain facial contours at deep tissue planes.

IPN-Like Technology™ contributes to gel stability and durability through an interpenetrating network structure that demonstrates enhanced resistance to degradation while maintaining flexibility and tissue integration. This allows practitioners to achieve natural-looking volumization without compromising structural support.

For practitioners asking how long STYLAGE® filler lasts, clinical and manufacturer-reported data suggest results from STYLAGE® XL treatments may persist for approximately 12–18 months, though longevity varies by factors such as skin type, treatment area, injection technique, metabolism, and lifestyle. Individual outcomes can differ significantly.

STYLAGE® XL BI-FLEX® with Lidocaine remains fully reversible. Licensed professionals can use hyaluronidase to dissolve the implanted HA gel if medically necessary.

STYLAGE® XL BI-FLEX® with Lidocaine injection is intended exclusively for qualified healthcare professionals trained in advanced injectable procedures. The product is generally placed into deep subcutaneous or supraperiosteal planes where significant structural support is required. The co-formulated lidocaine (3mg/mL) helps improve patient comfort during deep-plane injections, reducing the need for separate anesthetic injections while supporting procedural efficiency. Following treatment, patients should avoid excessive sun exposure, intense heat, and other environmental stressors until treatment-related reactions have resolved.

Side Effects & Potential Reactions

Common post-treatment reactions include

• Redness
• Swelling
• Tenderness
• Bruising
• Mild discomfort
• Temporary firmness at the injection site

These symptoms are typically transient and resolve within a few days, though swelling may persist slightly longer than with superficial fillers because of STYLAGE® XL’s deeper placement.

More serious effects include:

• Vascular Occlusion: Accidental intravascular injection can cause tissue ischemia and localized skin necrosis.
• Visual Disturbances: Embolization into the ocular arterial network carries a rare risk of permanent vision impairment.
• Emergency Protocols: Practitioners must maintain expert anatomical knowledge and be prepared to immediately administer hyaluronidase if vascular compromise occurs.
• Patient Screening: Contraindicated for individuals with known hypersensitivities to hyaluronic acid or amide-type local anesthetics.

For comprehensive safety guidelines and a complete risk assessment profile, refer to the manufacturer’s official instructions for use (IFU).

STYLAGE® XL BI-FLEX® with Lidocaine is manufactured by Laboratories VIVACY in France and is CE-marked for professional aesthetic use in applicable European markets. Regulatory requirements differ by jurisdiction; practitioners should verify local regulations, approved indications, and compliance requirements before use. Current FDA approval status should be confirmed through official regulatory channels. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact Maylips support team for sourcing information and documentation support.

For sourcing guidance, contact Maylips support team.

Regulatory information current as of mid 2026. Practitioners should confirm local regulatory status before sourcing.